Abstract
Introduction: Intermittent oral delivery of levodopa is a major contributing factor for motor complications in Parkinson's disease (PD). Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) into the jejunum using a portable pump via percutaneous endoscopic gastrostomy (PEG) improves motor complications and quality of life (QoL). Objectives: To record long-term effectiveness of advanced PD patients undergoing LCIG infusion in routine care, by Unified Parkinson's Disease Rating Scale (UPDRS), Non-Motor Symptoms Scale (NMSS), PDQ-8 and EQ-5D questionnaires. Methods: Overall, 375 patients from 75 movement disorder centers in 18 countries were enrolled in this prospective non-interventional study. The 12-month interim outcomes of the first 172 included patients are presented here. Results: There were reductions of mean daily "Off" time from baseline (BL) (7.1±3.5h) and "On" time with dyskinesias (5.2±4.5h) at month 12 (M12) of -4.7±3.4 and -1.7±5.0h respectively (p
| Original language | English |
|---|---|
| Pages (from-to) | 231-235 |
| Number of pages | 5 |
| Journal | Parkinsonism and Related Disorders |
| Volume | 21 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2015 |
Fingerprint
Keywords
- Advanced Parkinson's disease
- Duodenal levodopa-carbidopa infusion
- Motor symptoms
- Non-motor symptoms
- Quality of life
- Routine patient care
ASJC Scopus subject areas
- Geriatrics and Gerontology
- Clinical Neurology
- Neurology
- Medicine(all)
Cite this
Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. / Antonini, Angelo; Yegin, Ashley; Preda, Cornelia; Bergmann, Lars; Poewe, Werner.
In: Parkinsonism and Related Disorders, Vol. 21, No. 3, 01.03.2015, p. 231-235.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes
AU - Antonini, Angelo
AU - Yegin, Ashley
AU - Preda, Cornelia
AU - Bergmann, Lars
AU - Poewe, Werner
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Introduction: Intermittent oral delivery of levodopa is a major contributing factor for motor complications in Parkinson's disease (PD). Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) into the jejunum using a portable pump via percutaneous endoscopic gastrostomy (PEG) improves motor complications and quality of life (QoL). Objectives: To record long-term effectiveness of advanced PD patients undergoing LCIG infusion in routine care, by Unified Parkinson's Disease Rating Scale (UPDRS), Non-Motor Symptoms Scale (NMSS), PDQ-8 and EQ-5D questionnaires. Methods: Overall, 375 patients from 75 movement disorder centers in 18 countries were enrolled in this prospective non-interventional study. The 12-month interim outcomes of the first 172 included patients are presented here. Results: There were reductions of mean daily "Off" time from baseline (BL) (7.1±3.5h) and "On" time with dyskinesias (5.2±4.5h) at month 12 (M12) of -4.7±3.4 and -1.7±5.0h respectively (p
AB - Introduction: Intermittent oral delivery of levodopa is a major contributing factor for motor complications in Parkinson's disease (PD). Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) into the jejunum using a portable pump via percutaneous endoscopic gastrostomy (PEG) improves motor complications and quality of life (QoL). Objectives: To record long-term effectiveness of advanced PD patients undergoing LCIG infusion in routine care, by Unified Parkinson's Disease Rating Scale (UPDRS), Non-Motor Symptoms Scale (NMSS), PDQ-8 and EQ-5D questionnaires. Methods: Overall, 375 patients from 75 movement disorder centers in 18 countries were enrolled in this prospective non-interventional study. The 12-month interim outcomes of the first 172 included patients are presented here. Results: There were reductions of mean daily "Off" time from baseline (BL) (7.1±3.5h) and "On" time with dyskinesias (5.2±4.5h) at month 12 (M12) of -4.7±3.4 and -1.7±5.0h respectively (p
KW - Advanced Parkinson's disease
KW - Duodenal levodopa-carbidopa infusion
KW - Motor symptoms
KW - Non-motor symptoms
KW - Quality of life
KW - Routine patient care
UR - http://www.scopus.com/inward/record.url?scp=84923230653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923230653&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2014.12.012
DO - 10.1016/j.parkreldis.2014.12.012
M3 - Article
C2 - 25585993
AN - SCOPUS:84923230653
VL - 21
SP - 231
EP - 235
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
SN - 1353-8020
IS - 3
ER -